Quoin Pharmaceuticals Ltd DRC

Yahoo Finance • 4 days ago

Quoin Updates On Type C Meet With FDA For QRX003 In NS; On Track To Initiate Phase 3 Trial In 2026

(RTTNews) - Quoin Pharmaceuticals Ltd. (QNRX), a late-stage clinical company, provided a clinical and regulatory update following its recent Type C meeting with the U.S. Food and Drug Administration for its lead product candidate, QRX003,... Full story

Yahoo Finance • 5 months ago

Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results

– Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D – Sally Lawlor Appointed CFO to Support Commercialization and Financial Operations – Orphan Drug Designation Awarded by FDA to QRX003... Full story

Yahoo Finance • 5 months ago

Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025

ASHBURN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it pla... Full story

Yahoo Finance • 6 months ago

Top Midday Gainers

Quoin Pharmaceuticals (QNRX) shares soared 126% amid heavy trading intraday after the company said F PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 6 months ago

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million

ASHBURN, Va., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has... Full story

Yahoo Finance • 7 months ago

MSCI Shares Cross Above 200 DMA

In trading on Tuesday, shares of MSCI Inc (Symbol: MSCI) crossed above their 200 day moving average of $513.38, changing hands as high as $520.93 per share. MSCI Inc shares are currently trading up about 3.3% on the day. The chart below... Full story

Yahoo Finance • 7 months ago

Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome

ASHBURN, Va., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the releas... Full story

Yahoo Finance • 7 months ago

Quoin Pharmaceuticals appoints Sally Lawlor as CFO

* Quoin Pharmaceuticals (NASDAQ:QNRX [https://seekingalpha.com/symbol/QNRX]) on Monday announced the appointment of Sally Lawlor as its new Chief Financial Officer as the company advances its lead product candidate, QRX003, through pivot... Full story

Yahoo Finance • 7 months ago

Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appoint... Full story

Yahoo Finance • 8 months ago

Quoin Pharmaceuticals stock rises after positive clinical updates

Investing.com -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) stock rose 2.4% following the company’s update on its development product portfolio, highlighting progress in its lead product for Netherton Syndrome and other rare skin disease tre... Full story

Yahoo Finance • 8 months ago

Quoin Pharmaceuticals Provides Product Portfolio Update

Lead Product, QRX003, Being Tested in Two Active Registrational Clinical Studies for Netherton Syndrome Across the U.S., Europe, and the Middle East. QRX003 Peeling Skin Syndrome Clinical Program Continues Following Positive Initial Data... Full story

Yahoo Finance • 9 months ago

Quoin Pharmaceuticals CFO Gordon Dunn to depart following mutual agreement

Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX), a micro-cap pharmaceutical company with a market capitalization of $5.22 million, announced Monday that Chief Financial Officer Gordon Dunn will be leaving the company following a mutual agreement... Full story

Yahoo Finance • 9 months ago

Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases

ASHBURN, Va., June 26, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the release... Full story

Yahoo Finance • 10 months ago

Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study

Study CL-QRX003-002 will test whole-body application of QRX003 in conjunction with off-label systemic therapy in approximately 12-15 subjects.Study CL-QRX003-002 complements first whole-body pivotal study, CL-QRX003-003, being led by Dr. A... Full story

Yahoo Finance • 11 months ago

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study

Clear Improvement in Patient’s Skin Appearance Observed in Study after 12 weeks Compared to BaselineKey endpoints including Investigator’s Global Assessment (IGA), Modified Ichthyosis Area Severity (M-IASI) and Children’s Dermatology Life... Full story

Yahoo Finance • 12 months ago

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign

Episode Highlights a Truly Remarkable Patient Story Spanning 79 Years Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the company’s NETHERTON... Full story

Yahoo Finance • 12 months ago

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Continued Clear Visual Evidence of Almost Completely Healed Skin After 6 weeks TreatmentHigh Durability of Treatment Effect of QRX003 with Continuous Daily Dosing Patient Continues Not to Require Previously Necessary MedicationsWith Patien... Full story

Yahoo Finance • last year

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic DermatitisThird Quoin Patent Application for Netherton Syndrome If Granted Company Would have Patent Protection for QRX003 for... Full story

Yahoo Finance • last year

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Groundbreaking data from first whole body application of QRX003 underscores potential efficacyTransformational improvement in disease state after just 2 weeks of treatment Clear visual evidence of skin healing observedImprovement has elimi... Full story

Yahoo Finance • last year

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

ASHBURN, Va., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the launch... Full story